Stryker(US:SYK) ZACKS·2025-10-24 14:01Core Insights - Stryker Corporation (SYK) is set to announce its third-quarter 2025 results on October 30, with an earnings surprise of 2.29% in the last quarter [1] Q3 Estimates - The Zacks Consensus Estimate for earnings is $3.14 per share, reflecting a year-over-year increase of 9.4% [2] - Revenue consensus is projected at $6.04 billion, indicating nearly 10% growth from the previous year [2] - Total sales and adjusted earnings per share estimates are also at $6.04 billion and $3.15, respectively [2] Factors to Note - Stryker entered Q3 2025 following a strong Q2, which reported 10.2% organic sales growth, particularly in MedSurg and Neurotechnology divisions [3] Orthopaedics: Robotics Driving Hip and Knee Strength - The orthopaedics segment is expected to be a key growth driver, with the Mako robotic platform expanding globally [4] - Record installations of Mako were noted in Q2, supported by high utilization rates and the launch of Mako 4 [4] - Demand for robotic-assisted procedures remains strong, with hips and knees likely sustaining mid- to high-single-digit growth [4] MedSurg and Neurotechnology: Capital Demand Offsetting Supply Constraints - Capital equipment demand is robust, supported by strong hospital CapEx budgets and a healthy order backlog [6] - Endoscopy within MedSurg is expected to show double-digit growth, driven by the 1788 video platform and new product launches [6] - Neurotechnology is anticipated to maintain steady growth, bolstered by recent product rollouts [9] Inari Integration and Tariff Pressures - Stryker is managing the integration of Inari Medical, facing early challenges but expecting double-digit pro forma revenue growth in 2025 [10] - Tariff pressures are estimated to impact the company by $175 million annually, primarily affecting the second half of 2025 [11] - Despite these pressures, pricing discipline and manufacturing efficiencies are expected to mitigate some impacts on margins [11]